Phase I/II Study With the Combination of Dacomitinib and PD-0325901 in Metastatic KRAS Mutation Positive Non-small Cell Lung Cancer
Phase of Trial: Phase I/II
Latest Information Update: 29 Aug 2018
Price : $35 *
At a glance
- Drugs Mirdametinib (Primary) ; Capecitabine; Dacomitinib; Docetaxel; Irinotecan
- Indications Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Acronyms M13DAP
- 08 Nov 2017 Planned primary completion date changed from 1 Dec 2017 to 1 Dec 2018.
- 10 Nov 2016 Planned primary completion date changed from 1 Dec 2015 to 1 Dec 2017.
- 23 Jan 2014 New trial record